/Dexcom%20Inc%20logo%20on%20phone%20-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The San Diego, California-based company offers real-time blood glucose monitoring solutions to help patients and healthcare providers to manage diabetes globally. The company is expected to release its fiscal Q3 earnings results after the market closes on Thursday, Oct. 24.
Ahead of this event, analysts project the medical device company to report a profit of $0.44 per share, reflecting a 12% decrease from $0.50 per share in the year-ago quarter. However, the company has consistently surpassed Wall Street's bottom-line estimates in the last four quarterly reports. In the most recent quarter, DXCM posted an EPS of $0.43, surpassing the consensus estimate by 10.3%.